IRF4 Degradation · Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2019-04-01 → 2021-03-31
- Финансиране от ЕС
- 174 167 €
- Участници
- 1
- Схема
- MSCA-IF-EF-ST
Линиите свързват координатора с партньорите.
Накратко на български
Протеинът IRF4 регулира развитието на антителосекретиращите клетки, като за изследване на функциите му се използва метод за бързото му разграждане. Това помага за разбирането на молекулярните механизми при имунодефицити, автоимунни заболявания и рак от типа множествен миелом.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells
Antibody-secreting cells (ASCs) are an essential facet of the adaptive immune response. Their specialised role is to produce and secrete antibodies, which are important for neutralizing pathogens and providing long-lasting immunity to recurring infections. Defects in ASC development or function are associated with immunodeficiency, autoimmune disease, and cancer in the form of multiple myeloma. Despite the importance of ASCs in immunity and disease, little is known about how the development and function of these cells is regulated at the molecular level. ASCs develop from B cells that have been activated during an immune response. A striking feature of ASC differentiation is that the B cell undergoes a complete change in its gene expression programme. These changes are mediated by specific transcription factor proteins. IRF4 is an essential transcription factor for ASC development, and ASCs do not survive if the Irf4 gene is deleted. We sought to discover which genes are directly regulated by IRF4 in ASCs by depleting the IRF4 protein, rather than the gene, using an inducible degradation strategy (the auxin-inducible degradation, or AID, system). The advantage of this approach is depletion of IRF4 in the cell of interest, and thereby we could study gene expression changes that precede the loss of ASCs. The AID system requires tagging the protein of interest with a so-called degron (auxin inducible degron, or AID). Unfortunately, we learned that tagging IRF4 with an AID tag at the C-terminus of the protein disrupted the normal function of IRF4. We decided to proceed by moving the AID tag to the N-terminus of the protein. In the meantime, we were simultaneously generating AID-tagged versions of other proteins essential for ASC development, namely E2A and E2-2. Therefore, the project changed focus to these different transcription factors in order to develop the protocols for auxin-induced degradation and SLAMseq in ASCs. In addition, E2A is required for the development of the B cell lineage (i.e. ASC precursors) at a much earlier developmental stage, the pro-B cell. Pro-B cells are easier to work with in culture than ASCs, and so we could use E2A-AID degradation and SLAMseq analysis in pro-B cells as proof-of-concept for our ASC studies. In doing so, we would also learn about the genes and pathways, regulated by E2A, which are essential for the development of the B cell lineage at the pro-B cell stage.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Plasma cells (PCs) are antibody-producing cells that develop from activated B cells in an immune response. Antibodies produced by these cells are essential for the clearance of pathogens and long-term protection against recurrent infections. PCs can also be pathogenic in autoimmune disease, where self-recognising antibodies are produced, and cancer, in the form of multiple myeloma. An understanding of the molecular pathways that control PC function is therefore necessary for understanding human immunity and these pathologies. Interferon Regulatory Factor 4 (IRF4, gene name Irf4) is a transcription factor whose deletion in mouse models results in the loss of all PCs. Because of this, the genes that are regulated by IRF4, and hence which cellular pathways are required for PC survival, are unknown. Here, I propose to use a revolutionary approach to determine the target genes of IRF4. I will use targeted protein degradation to deplete IRF4 in mouse PCs, and then determine the immediate changes in transcription following IRF4 loss using a state-of-the-art RNA sequencing technique, known as SLAM-seq. The advantage of this approach is that I can analyze changes in transcription before the onset of the survival defect. I will then study the functional roles of the identified IRF4 target genes in PCs. This is a multidisciplinary project that combines molecular biology approaches with cell biology and immune physiology. In addition, this proposal allows for transfer of knowledge from myself, an expert in the regulation of cell survival, and the host institution, which will train me in molecular biology techniques and expertise in PC biology. IRF4 has been implicated in both autoimmune disease and multiple myeloma, and so this proposal addresses a basic research question that has translatable outcomes. Hence, this proposal is in line with the H2020 objective to increase the transfer of knowledge into tangible products, and contributes to the European knowledge-based economy.
Оригинален текст от CORDIS (на английски).
Участници
- FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH · WienКоординаторАвстрия
Връзки
Данни: CORDIS, © Европейски съюз
